Analysis of-the P53, RB/D13S25, and P16 tumor suppressor genes in marginal zone B-cell lymphoma:: An interphase fluorescence in situ hybridization study

被引:13
作者
Dierlamm, J
Stefanova, M
Wlodarska, I
Hinz, K
Maes, B
Michaux, L
Stul, M
Verhoef, G
Thomas, J
De Wolf-Peeters, C
Van den Berghe, H
Hossfeld, HK
Hagemeijer, A
机构
[1] Ctr Human Genet, B-3000 Louvain, Belgium
[2] Univ Hamburg, Hosp Eppendorf, Dept Hematol & Oncol, D-20246 Hamburg, Germany
[3] Univ Leuven, Dept Pathol, Louvain, Belgium
[4] Univ Leuven, Dept Hematol, Louvain, Belgium
[5] Univ Leuven, Dept Oncol, Louvain, Belgium
关键词
D O I
10.1016/S0165-4608(99)00239-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The genetic mechanisms underlying the genesis, disease progression, and high-grade transformation of marginal zone B-cell lymphoma (MZBCL) are poorly understood. We analyzed 33 cases of histologically and immunophenotypically well-characterized MZBCL (12 extranodal, ii nodal, and 10 splenic MZBCL; 27 at primary diagnosis and six during the course of disease) by dual-color interphase fluorescence in situ hybridization (FISH) for deletions of tumor suppressor genes. We investigated loci known to play a role in the genesis or disease progression of other subtypes of lymphoid malignancies, namely the P53 gene (17p13), the retinoblastoma gene (RE, 13q14), the D13S25 locus (13q14), and the P16(INK4A) gene (9p21). Heterozygous deletions of P53 were detected in three out of the 33 cases, including two splenic and one extranodal MZBCL. One of these patients was analyzed at primary diagnosis and two during the course of disease. Heterozygous deletions of the RE gene (nodal MZBCL) and D13825 (splenic MZBCL) were found in one case each. P16 deletions were not detected in any of our cases. We conclude that deletions of the analyzed tumor suppressor genes are relatively rare in MZBCL, which contrasts with the findings in some other subtypes of NHL. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 40 条
[1]  
BALDINI L, 1994, BLOOD, V84, P270
[2]  
Bentz M, 2000, GENE CHROMOSOME CANC, V27, P285, DOI 10.1002/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.3.CO
[3]  
2-D
[4]  
Dierlamm J, 1996, GENE CHROMOSOME CANC, V16, P261, DOI 10.1002/(SICI)1098-2264(199608)16:4<261::AID-GCC6>3.0.CO
[5]  
2-W
[6]   Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization [J].
Dierlamm, J ;
Rosenberg, C ;
Stul, M ;
Pittaluga, S ;
Wlodarska, I ;
Michaux, L ;
Dehaen, M ;
Verhoef, G ;
Thomas, J ;
deKelver, W ;
BakkerSchut, T ;
Cassiman, JJ ;
Raap, AK ;
DeWolfPeeters, C ;
VandenBerghe, H ;
Hagemeijer, A .
LEUKEMIA, 1997, 11 (05) :747-758
[7]   The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas [J].
Dierlamm, J ;
Baens, M ;
Wlodarska, I ;
Stefanova-Ouzounova, M ;
Hernandez, JM ;
Hossfeld, DK ;
De Wolf-Peeters, C ;
Hagemeijer, A ;
Van den Berghe, H ;
Marynen, P .
BLOOD, 1999, 93 (11) :3601-3609
[8]   Trisomy 3 in marginal zone B-cell lymphoma: A study based on cytogenetic analysis and fluorescence in situ hybridization [J].
Dierlamm, J ;
Michaux, L ;
Wlodarska, I ;
Pittaluga, S ;
Zeller, W ;
Stul, M ;
Criel, A ;
Thomas, J ;
Boogaerts, M ;
Delaere, P ;
Cassiman, JJ ;
DeWolfPeeters, C ;
Mecucci, C ;
VandenBerghe, H .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (01) :242-249
[9]  
Dierlamm J, 1996, BLOOD, V87, P299
[10]   P53 GENE DELETION PREDICTS FOR POOR SURVIVAL AND NONRESPONSE TO THERAPY WITH PURINE ANALOGS IN CHRONIC B-CELL LEUKEMIAS [J].
DOHNER, H ;
FISCHER, K ;
BENTZ, M ;
HANSEN, K ;
BENNER, A ;
CABOT, G ;
DIEHL, D ;
SCHLENK, R ;
COY, J ;
STILGENBAUER, S ;
VOLKMANN, M ;
GALLE, PR ;
POUSTKA, A ;
HUNSTEIN, W ;
LICHTER, P .
BLOOD, 1995, 85 (06) :1580-1589